数据
资源
版本对比
免费注册
预约演示
免费注册
Health Canada Approves
KEYTRUDA
® for adult patients with
locally advanced unresectable or metastatic biliary tract carcinoma
, in combination with
gemcitabine
-based chemotherapy
2024-05-09
·
BioSpace
临床结果
临床3期
上市批准
Approval is based on the Phase 3 KEYNOTE-966 Trial KIRKLAND, QC, May 9, 2024 /CNW/ -
Merck
(NYSE: MRK), known as
MSD
outside the United States and Canada, announced that Health Canada has granted approval of
KEYTRUDA
® (
pembrolizumab
),
Merck
's anti-
PD-1
therapy, in combination with
gemcitabine
-based chemotherapy, for the treatment of adult patients with
locally advanced unresectable or metastatic biliary tract carcinoma (BTC)
. This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus chemotherapy alone. "
Biliary tract cancer
is usually diagnosed at an advanced stage, where patient survival rates are poor," says André Galarneau, PhD, Executive Director & Vice President, Oncology Business Unit at
Merck Canada
. "The addition of this indication shows promising overall survival results, which means more potential treatment options for
biliary cancer
patients in urgent need." About KEYNOTE-966 KEYNOTE-966 was a multicentre, randomized, double-blind, placebo-controlled Phase 3 trial (ClinicalTrials.gov NCT04003636) evaluating
pembrolizumab
in combination with
gemcitabine
and
cisplatin
compared to placebo plus
gemcitabine
and
cisplatin
for the first-line treatment of advanced and/or unresectable BTC. The primary endpoint was OS, and the secondary endpoints included progression-free survival (PFS), objective response rate (ORR), as assessed by BICR according to RECIST v1.1. The trial enrolled 1,069 patients with locally advanced unresectable or metastatic BTC, who had not received prior systemic therapy in the advanced disease setting. Patients were randomized (1:1) to receive
pembrolizumab
(200 mg every three weeks for up to approximately two years) plus
gemcitabine
and
cisplatin
, or placebo plus
gemcitabine
and
cisplatin
. Treatment continued until unacceptable toxicity or disease progression. For
pembrolizumab
, treatment continued for a maximum of 35 cycles, or approximately 24 months. For
cisplatin
, treatment could be administered for a maximum of 8 cycles and for
gemcitabine
, treatment could be continued beyond 8 cycles.
Pembrolizumab
with the
gemcitabine
/
cisplatin
arm demonstrated a clinically meaningful and statistically significant improvement versus the placebo with
gemcitabine
/
cisplatin
arm in OS. In the study, there was a 17% reduction in the risk of death with
pembrolizumab
plus
gemcitabine
/
cisplatin
(HR=0.83 [95% CI, 0.72-0.95]; p=0.0034) versus
gemcitabine
/
cisplatin
alone. The median PFS was 6.5 months (95% CI, 5.7-6.9) for the
pembrolizumab
plus chemotherapy arm versus 5.6 months (95% CI, 5.1,6.6) for the placebo plus chemotherapy arm. The objective response rate at the pre-specified interim analysis was 28.7% (24.9, 32.8) versus 28.5% (24.8, 32.6) respectively. The most common treatment-related adverse events (reported in at least 20% of patients) were neutrophil count decreased,
anemia
, platelet count decreased,
nausea
,
fatigue
, and white blood cell count decreased. For complete information, refer to the
KEYTRUDA
® product monograph. About
Biliary Tract Cancer
Biliary tract cancer
is a group of rare and highly aggressive
cancers
in the gallbladder and bile ducts.
Biliary tract cancer
is the second most common type of
primary liver cancer
after
hepatocellular carcinoma
, accounting for 15% of all
liver cancers
. It is estimated there are approximately 211,000 new cases of BTC diagnosed and 174,000 deaths from the disease each year globally.
Biliary tract cancer
is most frequently diagnosed in patients between 50 to 70 years old, and 60-70% of BTC patients are diagnosed at an advanced stage. Patients diagnosed with BTC face a very poor prognosis, as the five-year survival rate is estimated to be between 5% and 15%. About
KEYTRUDA
®
KEYTRUDA
® is an anti-
programmed death receptor-1 (PD-1)
therapy that works by helping increase the ability of the body's immune system to help detect and fight
tumour
cells.
KEYTRUDA
® is a humanized monoclonal antibody that blocks the interaction between
PD-1
and its ligands,
PD-L1
and
PD-L2
, thereby activating T lymphocytes which may affect both
tumour
cells and healthy cells.
KEYTRUDA
® was first approved in Canada in 2015 and currently has indications in several disease areas, including
advanced renal cell carcinoma
,
bladder cancer
,
non-small cell lung carcinoma
,
primary mediastinal B-cell lymphoma
, classical Hodgkin lymphoma,
colorectal cancer
,
endometrial carcinoma
,
cervical cancer
,
esophageal cancer
,
triple-negative breast cancer
,
melanoma
, and
head and neck squamous cell carcinoma
. About
Merck
At
Merck
, known as
MSD
outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit and connect with us on LinkedIn and X @MerckCanada. Forward-Looking Statement of
Merck & Co. Inc.
, Rahway, NJ, USA This news release of
Merck & Co., Inc.
, Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( ). Please see the product monograph for
KEYTRUDA
® (
pembrolizumab
) at Merck.ca. ®
Merck Sharp & Dohme LLC.
Used under license. © 2024
Merck & Co., Inc.
, Rahway, NJ, USA and its affiliates. All rights reserved. SOURCE
Merck Canada Inc.
Company Codes: NYSE:MRK
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Merck & Co., Inc.
Merck Canada, Inc.
Merck Sharp & Dohme LLC
适应症
转移性胆道癌
胆道肿瘤
贫血
[+17]
靶点
PD-1
PDL1
PDL2
药物
帕博利珠单抗
吉西他滨
顺铂
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务